Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Guangdong Second Provincial General Hospital | OTHER |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | OTHER |
| Guangzhou First People's Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic Obstructive Pulmonary Disease (COPD) is a worldwide common disease with high morbidity and mortality and leads to heavy social and economic burden. Health management of stable COPD patients has been suggested to be essential for delaying diseases progress, reducing acute exacerbation events and improving patient quality of life. Non-invasive ventilation (NIV) is a widely used treatment in COPD patients. There were studies shown that NIV could improve ventilation, blood gases etc., and several clinical trials have shown improvements in survival, exercise capacity, quality of life and so on. Compliance to NIV and optimal parameter setting are important factors that will affect the effect of the use of NIV, thus NIV usage monitoring might also be a crucial element in the health management of COPD patients. Many studies have been designed to study the effect of tele-monitoring program on the management of COPD patients. However, almost none of these studies were designed for specific population, and little is known about the effect of such program on the management of patients with NIV treatment.
The COPD home management program consists of 3 Philips devices (NIV BiPAP ST, Oximeter and Blood Pressure Meter), a patient mobile APP which is developed for self-management at home and a professional physician web portal which is designed for NIV usage and other vital sign data monitoring. The program is intended to manage the post-discharge COPD patient by enhancing COPD patient condition monitoring and adherence to the home therapy, e.g. NIV in this study. Besides obtaining clinical proof points of the efficacy of such program on patients with NIV treatment, it will provide potential evidence of the usability as well as the collect the insights for future product improvement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials. Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly. |
|
| Control group | No Intervention | Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NIV with the integrated tele-monitoring management program | Device | Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly. |
| Measure | Description | Time Frame |
|---|---|---|
| Adherence to NIV treatment | The primary objective is to test the effect of COPD tele-monitoring program on patient's adherence to NIV treatment. | 12th month |
| Measure | Description | Time Frame |
|---|---|---|
| Acute exacerbation of COPD re-admission rate | Acute exacerbation which was characterized as an acute worsening of more than one respiratory symptom (new onset of or increase in sputum volume or purulence, wheezing, cough, dyspnoea, or fever) lasting for at least 2 consecutive days and result in any changes in their conventional therapy. | Baseline, 1st, 3rd, 6th and 12th month |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Luqian Zhou, PhD | Contact | +8615622236759 | zhlx09@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Rongchang Chen, MD | Guangzhou Institute of Respiratory Health | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Guangzhou Medical University. | Recruiting | Guangzhou | Guangdong | 510120 | China |
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D012131 | Respiratory Insufficiency |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D063087 | Noninvasive Ventilation |
| ID | Term |
|---|---|
| D012121 | Respiration, Artificial |
| D058109 | Airway Management |
| D013812 | Therapeutics |
| D012138 | Respiratory Therapy |
Not provided
Not provided
| Dongguan People's Hospital |
| OTHER_GOV |
| Huizhou Municipal Central Hospital | OTHER |
| Shenzhen People's Hospital | OTHER |
| Clifford Hospital, Guangzhou, China | OTHER |
| Shenzhen Sixth People's Hospital | OTHER |
| Subei People's Hospital of Jiangsu Province | OTHER |
Not provided
Not provided
Not provided
Not provided
|
| Severe Respiratory Insufficiency (SRI) Questionnaire | The SRI Questionnaire has good psychometric properties shown to be valid for chronic hypercapnic COPD patients receiving NIV. It includes 49 items on seven subscales. | Baseline, 3rd, 6th and 12th month |
| COPD assessment test | The COPD Assessment Test is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. | Baseline, 1st, 3rd, 6th and 12th month |
| Partial pressure of arterial blood carbon dioxide (PaCO2) | Daytime arterial blood gas samples were taken with patients resting in a sitting position and breathing room air without having used NIV for at least 1 hour. | Baseline, 1st, 3rd, 6th and 12th month |
| 6-minute walk test | The 6-minute walk test plays a key role in evaluating functional exercise capacity, assessing prognosis and evaluating response to treatment across a wide range of respiratory diseases. | Baseline, 3rd, 6th and 12th month |
| Forced vital capacity | Forced vital capacity is measured in a test known as spirometry, a type of pulmonary function test, which is used to help determine both the presence and severity of lung diseases. | Baseline, 3rd, 6th and 12th month |
| Forced expiratory volume in 1 second | Forced expiratory volume in 1 second is a marker used to measure lung function and can help you monitor your lung diseases over time. | Baseline, 3rd, 6th and 12th month |
| Baseline Dyspnea Index/Transition Dyspnea Index | Baseline Dyspnea Index/Transition Dyspnea Index provides a multidimensional measurement of dyspnea based on 3 components that evoke dyspnea in activities of daily living, in symptomatic individuals. | Baseline, 3rd, 6th and 12th month |
| COPD self-efficacy scale | Identifying situations in which individuals with COPD experience low self-efficacy is important. | Baseline, 6th and 12th month |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012120 | Respiration Disorders |